DDInter1042 DDInter1744
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Tamoxifen {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tamoxifen {u} (Compound) resembles {v} (Compound) Naftifine
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Diphenhydramine
Tamoxifen {u} (Compound) treats {v} (Disease) breast cancer
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2E1
Tamoxifen {u} (Compound) upregulates {v} (Gene) SC5D
Tamoxifen {u} (Compound) downregulates {v} (Gene) CCNB2
Tamoxifen {u} (Compound) causes {v} (Side Effect) Thirst
Tamoxifen (Compound) resembles Methadyl Acetate (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tamoxifen (Compound) resembles Naftifine (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
Tamoxifen (Compound) treats breast cancer (Disease)
Tamoxifen (Compound) binds CYP2E1 (Gene)
Tamoxifen (Compound) upregulates SC5D (Gene)
Tamoxifen (Compound) downregulates CCNB2 (Gene)
Tamoxifen (Compound) causes Thirst (Side Effect)